ISIS had 2 approvals by FDA in past but both failed in Market.
Isis has several drugs in clinical development. However, only two have reached the market. One is Vitravene, for an AIDS-related viral eye infection, approved for sale in 1997. Vitravene is no longer sold, because new HIV drugs have reached the market. Another Isis drug, alicaforsen, was licensed to Atlantic Pharmaceuticals in 2007. Atlantic sells the drug for inflamatory bowel disease and related conditions.
Isis developed Kynamro and then licensed the potential treatment to Genzyme, which will market the drug if it is approved.
In baseball, you do have to swing at pitches to make home runs, but every swing will not be a home run. In drug development, some drugs will be superceded by others that show more potential or cost less. If you don't enjoy watching the game or paying the attendance fee, go elsewhere. There are some big bats in the next inning.